Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients
Abstract Objective To evaluate the ability of 68Ga‐PSMA PET/CT maximum standard uptake value (SUVmax) to distinguish prostate cancer (PCa) International Society of Urological Pathology ISUP grade group (GG) 2 and GG3. Methods The PET/CT images and data of 147 patients were analyzed retrospectively,...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5516 |
| _version_ | 1827974975170019328 |
|---|---|
| author | Nuo Yi Yajing Wang Shiming Zang Lulu Yang Hao Liu Hongbin Sun Liwei Wang Feng Wang |
| author_facet | Nuo Yi Yajing Wang Shiming Zang Lulu Yang Hao Liu Hongbin Sun Liwei Wang Feng Wang |
| author_sort | Nuo Yi |
| collection | DOAJ |
| description | Abstract Objective To evaluate the ability of 68Ga‐PSMA PET/CT maximum standard uptake value (SUVmax) to distinguish prostate cancer (PCa) International Society of Urological Pathology ISUP grade group (GG) 2 and GG3. Methods The PET/CT images and data of 147 patients were analyzed retrospectively, and the SUVmax of the index lesions were measured. The receiver operating characteristic curve was used to analyze the diagnostic value of PET/CT for PCa. The correlation between SUVmax and ISUP GG was analyzed. A logistic regression model was established with SUVmax and was validated to predict its value of diagnosing intermediate‐ and high‐risk PCa (ihPCa). Results Of the 147 patients, 112 cases were PCa (76.2%), and 35 cases were benign lesions (23.8%). There was a significant difference between the benign and the malignant groups (p < 0.05). The median SUVmax of ihPCa was significantly higher than that of the benign and low‐risk groups (p < 0.05). The median SUVmax of GG3 was significantly higher than that of the GG2 group (p < 0.05). There were no statistically significant SUVmax differences among GG3, GG4, and GG5 groups (p > 0.05). The specificity and the positive predictive value of 68Ga‐PSMA PET/CT in the diagnosis of PCa were 97% and 99% with cut‐off SUVmax of 6.94, while the specificity and the positive predictive value of ihPCa were 95% and 96% with cut‐off SUVmax of 10.12. Conclusion 68Ga‐PSMA PET/CT can reliably distinguish GG2 from GG3 PCa. |
| first_indexed | 2024-04-09T20:02:49Z |
| format | Article |
| id | doaj.art-49e6d14034c24f1f8fd906154900a642 |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T20:02:49Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-49e6d14034c24f1f8fd906154900a6422023-04-02T20:55:00ZengWileyCancer Medicine2045-76342023-03-011267140714810.1002/cam4.5516Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patientsNuo Yi0Yajing Wang1Shiming Zang2Lulu Yang3Hao Liu4Hongbin Sun5Liwei Wang6Feng Wang7Department of Radiology, Nanjing First Hospital Nanjing Medical University Nanjing ChinaDepartment of Radiology, Nanjing First Hospital Nanjing Medical University Nanjing ChinaDepartment of Nuclear Medicine, Nanjing First Hospital Nanjing Medical University Nanjing ChinaDepartment of Pathology, Nanjing First Hospital Nanjing Medical University Nanjing ChinaDepartment of Radiology, Nanjing First Hospital Nanjing Medical University Nanjing ChinaDepartment of Urology, Nanjing First Hospital Nanjing Medical University Nanjing ChinaDepartment of Radiology, Nanjing First Hospital Nanjing Medical University Nanjing ChinaDepartment of Nuclear Medicine, Nanjing First Hospital Nanjing Medical University Nanjing ChinaAbstract Objective To evaluate the ability of 68Ga‐PSMA PET/CT maximum standard uptake value (SUVmax) to distinguish prostate cancer (PCa) International Society of Urological Pathology ISUP grade group (GG) 2 and GG3. Methods The PET/CT images and data of 147 patients were analyzed retrospectively, and the SUVmax of the index lesions were measured. The receiver operating characteristic curve was used to analyze the diagnostic value of PET/CT for PCa. The correlation between SUVmax and ISUP GG was analyzed. A logistic regression model was established with SUVmax and was validated to predict its value of diagnosing intermediate‐ and high‐risk PCa (ihPCa). Results Of the 147 patients, 112 cases were PCa (76.2%), and 35 cases were benign lesions (23.8%). There was a significant difference between the benign and the malignant groups (p < 0.05). The median SUVmax of ihPCa was significantly higher than that of the benign and low‐risk groups (p < 0.05). The median SUVmax of GG3 was significantly higher than that of the GG2 group (p < 0.05). There were no statistically significant SUVmax differences among GG3, GG4, and GG5 groups (p > 0.05). The specificity and the positive predictive value of 68Ga‐PSMA PET/CT in the diagnosis of PCa were 97% and 99% with cut‐off SUVmax of 6.94, while the specificity and the positive predictive value of ihPCa were 95% and 96% with cut‐off SUVmax of 10.12. Conclusion 68Ga‐PSMA PET/CT can reliably distinguish GG2 from GG3 PCa.https://doi.org/10.1002/cam4.5516positron emission tomographyprostate cancerprostate‐specific membrane antigen |
| spellingShingle | Nuo Yi Yajing Wang Shiming Zang Lulu Yang Hao Liu Hongbin Sun Liwei Wang Feng Wang Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients Cancer Medicine positron emission tomography prostate cancer prostate‐specific membrane antigen |
| title | Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients |
| title_full | Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients |
| title_fullStr | Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients |
| title_full_unstemmed | Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients |
| title_short | Ability of 68Ga‐PSMA PET/CT SUVmax to differentiate ISUP GG2 from GG3 in intermediate‐risk prostate cancer: A single‐center retrospective study of 147 patients |
| title_sort | ability of 68ga psma pet ct suvmax to differentiate isup gg2 from gg3 in intermediate risk prostate cancer a single center retrospective study of 147 patients |
| topic | positron emission tomography prostate cancer prostate‐specific membrane antigen |
| url | https://doi.org/10.1002/cam4.5516 |
| work_keys_str_mv | AT nuoyi abilityof68gapsmapetctsuvmaxtodifferentiateisupgg2fromgg3inintermediateriskprostatecancerasinglecenterretrospectivestudyof147patients AT yajingwang abilityof68gapsmapetctsuvmaxtodifferentiateisupgg2fromgg3inintermediateriskprostatecancerasinglecenterretrospectivestudyof147patients AT shimingzang abilityof68gapsmapetctsuvmaxtodifferentiateisupgg2fromgg3inintermediateriskprostatecancerasinglecenterretrospectivestudyof147patients AT luluyang abilityof68gapsmapetctsuvmaxtodifferentiateisupgg2fromgg3inintermediateriskprostatecancerasinglecenterretrospectivestudyof147patients AT haoliu abilityof68gapsmapetctsuvmaxtodifferentiateisupgg2fromgg3inintermediateriskprostatecancerasinglecenterretrospectivestudyof147patients AT hongbinsun abilityof68gapsmapetctsuvmaxtodifferentiateisupgg2fromgg3inintermediateriskprostatecancerasinglecenterretrospectivestudyof147patients AT liweiwang abilityof68gapsmapetctsuvmaxtodifferentiateisupgg2fromgg3inintermediateriskprostatecancerasinglecenterretrospectivestudyof147patients AT fengwang abilityof68gapsmapetctsuvmaxtodifferentiateisupgg2fromgg3inintermediateriskprostatecancerasinglecenterretrospectivestudyof147patients |